Phase I and pharmacokinetic evaluation of thiotepa in the cerebrospinal fluid and plasma of pediatric patients: evidence for dose-dependent plasma clearance of thiotepa.

@article{Heideman1989PhaseIA,
  title={Phase I and pharmacokinetic evaluation of thiotepa in the cerebrospinal fluid and plasma of pediatric patients: evidence for dose-dependent plasma clearance of thiotepa.},
  author={Richard L. Heideman and David Edward C Cole and Frank M Balis and Jiro Sato and Gregory H. Reaman and Roger J. Packer and L J Singher and Lawrence J. Ettinger and Andy Gillespie and Joseph W. Sam},
  journal={Cancer research},
  year={1989},
  volume={49 3},
  pages={736-41}
}
A Phase I trial of thiotepa (TT) administered as an i.v. bolus was performed in 19 children with refractory malignancies. The starting dose was 25 mg/m2 with escalations to 50, 65, and 75 mg/m2. Seven additional patients were treated with 8-h infusions at 50 or 65 mg/m2. The maximum tolerated bolus dose was 65 mg/m2. Reversible myelosuppression was the dose-limiting toxicity. The plasma and cerebrospinal fluid (CSF) pharmacokinetic parameters of TT and its major active metabolite tepa (TP) were… CONTINUE READING
51 Citations
25 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 51 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 25 references

3Unpublished observations, manuscript in preparation

  • B. E. Cohen, M. J. Egorin, A. A. Kohlhepp, J. Aisner, P. Gutierrez
  • 740 on April
  • 1989
2 Excerpts

High-dose .V,.V,.V"-triirthylenctliiophosphor:inndc (thiotepa) and autologous bone marrow transplantation (AMT) for refractory malignancies

  • R. Brown, R. Herzig, +4 authors G. Herzig
  • Proc. Am. Soc. Clin. Oncol.,
  • 1986
1 Excerpt

Similar Papers

Loading similar papers…